Month: June 2023

MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months All patients were refractory to BTK inhibitors, and no patients have started new anti-WM treatment after MB-106 Currently no FDA-approved CAR T treatments for WM WORCESTER, Mass., June 12, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety and efficacy...

Virtual presentation on Thursday, June 15, 2023, at 1:45 PM ET NEW YORK, June 12, 2023 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company with over $4 billion in retail sales generated by its brands through livestreaming alone and over 10,000 hours of show programming time, today announced that it will be presenting and hosting one-on-one meetings at the Sidoti & Company Small-Cap Virtual Investor Conference on Wednesday, June 14 and Thursday, June 15. Robert W. D’Loren, Chairman and Chief Executive Officer of Xcel Brands, will be leading the formal presentation and answering questions from investors on Thursday, June 15 at 1:45 p.m. ET. Xcel Brands will provide an overview on its growth opportunities and business transformation, including the recent 25-year...

The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn Loftsson.OPTIREACH is behind Oculis’ lead candidate OCS-01, currently in Phase 3 development in patients with Diabetic Macular Edema (DME) and for the treatment of inflammation and pain following cataract surgery.The revolutionary and proprietary OPTIREACH technology enables the formulation of topical eye drops to reach the back-of-the-eye at therapeutic concentration, as shown in the recent positive and robust clinical trial results from the DIAMOND program with OCS-01 in DME.The award also recognizes the successful journey of Oculis internationally and in broadening its portfolio with other novel and promising drug candidates for eye diseases including OCS-02, a topical...

AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We” or “Our”), annouces the beta unveiling of a pioneering press releases (“PR”) chatbot. This chatbot is set to redefine user interaction by providing interactive responses to all our press releases through April 24, 2023. Our PR chatbot is open to all users, with no restriction on token holder status, thus inviting everyone to experience the seamless comparison of our PR chatbot with traditional ChatGPT. You can explore this firsthand on our website, as shown below. As we refine and perfect our beta version of our PR chatbot, your insights and feedback are invaluable. We welcome your thoughts at token@pet2dao.com. “We are thrilled to introduce our second chatbot...

Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approvedFLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that its New Drug Application (NDA) resubmission for vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease) constitutes a complete response to the February 2023 complete response letter (CRL). The FDA has classified this as a Class 2 resubmission and assigned a Prescription...

Closing of the sale of Espoir Ivoirien BW Offshore has today closed the transaction for the sale of the FPSO Espoir Ivoirien to its client for a total consideration of USD 20 million. Following the transaction, BW Offshore will provide transitional O&M (Operations and Maintenance) services for a period of up to five months. For further information, please contact:Ståle Andreassen, CFO, +47 91 71 86 55Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore:BW Offshore engineers innovative floating production solutions. The Company has a fleet of 7 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore...

Figure 1 Trailbreaker and Vizsla Copper claims with the optioned groundVANCOUVER, British Columbia, June 12, 2023 (GLOBE NEWSWIRE) — Trailbreaker Resources Ltd. (TBK.V) (“Trailbreaker” or “the Company”) is pleased to announce the signing of an option agreement with Vizsla Copper Corp. (“Vizsla Copper”) for a portion of Trailbreaker’s Eagle Lake property. The Eagle Lake property borders Vizsla Copper’s Woodjam copper-gold porphyry project. The option deal includes four of the fourteen claims comprising Eagle Lake. The four claims account for 6,482 hectares (ha) of the 19,000 ha property (see Figure 1). Daithi Mac Gearailt, CEO of Trailbreaker, commented: “We are very pleased to come to an arrangement with Vizsla Copper. This is a win-win deal: Vizsla gets to acquire and explore ground to expand their Woodjam project, while Trailbreaker...